31 May, 2023: 3M, a company known for its expertise in industrial equipment manufacturing, intends to allocate £120 million to enhance its capacities in order to provide greater assistance to the rapidly expanding field of biotech manufacturing. The investment will involve enhancing facilities and equipment, along with the establishment of 60 additional full-time positions at 3M's manufacturing sites in Europe.

The latest infusion of funds will expedite 3M's progress in creating and supplying crucial filtration devices specifically tailored for bioprocessing, biological, and small molecule pharmaceutical production. These advanced equipment offerings will empower its biotechnology clients to sustain their cutting-edge developments in therapeutic solutions aimed at addressing ailments like rheumatoid arthritis, multiple sclerosis and certain forms of cancer. The manufacturing of biopharmaceutical drugs heavily relies on filtration and purification, a vital procedure employing a distinct filter that effectively captures impurities while permitting the passage of essential drug components.

In the company’s official press release, Robert Befidi, President, 3M Separation and Purification Sciences Division said, "Our investment further demonstrates 3M's continued market leadership and ongoing commitment to customer-centric innovation in health care. Our technologies improve the lives of people all over the world, and we are helping biotech customers do more, faster, to advance their specialised medicines."

3M provides the most extensive range of depth filters for cell culture clarification in the biopharmaceutical sector. The company’s Zeta Plus™ depth filtration technology is crucial in clarifying cell-based protein therapeutic products globally, available in both cartridge systems and sheets.

With such significant investment, the future holds great promise for advancements in drug manufacturing and the overall improvement of global healthcare. As these investments materialise into tangible advancements, the positive impact on patients and the biopharma sector as a whole will undoubtedly be substantial.